Matching articles for "Zorvolex"

Comparison Table: Some Nonopioid Analgesics for Pain (online only)

   
The Medical Letter on Drugs and Therapeutics • March 7, 2022;  (Issue 1645)
...
View the Comparison Table: Some Nonopioid Analgesics for Pain
Med Lett Drugs Ther. 2022 Mar 7;64(1645):e40-3 | Show Full IntroductionHide Full Introduction

Nonopioid Drugs for Pain

   
The Medical Letter on Drugs and Therapeutics • March 7, 2022;  (Issue 1645)
Nonopioid drugs can be used in the treatment of many nociceptive and neuropathic pain conditions. For severe pain, especially severe chronic cancer pain, use of opioids may be necessary....
Nonopioid drugs can be used in the treatment of many nociceptive and neuropathic pain conditions. For severe pain, especially severe chronic cancer pain, use of opioids may be necessary. Noninvasive nonpharmacologic treatments, including physical and psychological therapies, have been shown to improve pain and function in patients with some common chronic pain conditions and are unlikely to cause serious harms. A multimodal approach to analgesic therapy can increase pain control while reducing opioid use and adverse effects.
Med Lett Drugs Ther. 2022 Mar 7;64(1645):33-40 | Show Full IntroductionHide Full Introduction

Drugs for Osteoarthritis

   
The Medical Letter on Drugs and Therapeutics • April 20, 2020;  (Issue 1596)
Many different drugs are used for treatment of osteoarthritis pain, but none of them prevent progression of the disease. Nonpharmacologic approaches including weight management, exercise, tai chi, physical...
Many different drugs are used for treatment of osteoarthritis pain, but none of them prevent progression of the disease. Nonpharmacologic approaches including weight management, exercise, tai chi, physical therapy, assistive devices, and total joint arthroplasty can also be used. The American College of Rheumatology (ACR) has published new guidelines for the management of osteoarthritis of the hip, hand, and knee.
Med Lett Drugs Ther. 2020 Apr 20;62(1596):57-62 | Show Full IntroductionHide Full Introduction

Nonopioid Drugs for Pain

   
The Medical Letter on Drugs and Therapeutics • February 12, 2018;  (Issue 1540)
Nonopioid drugs can be used in the treatment of many nociceptive and neuropathic pain conditions. Use of opioids for pain will be reviewed in a future...
Nonopioid drugs can be used in the treatment of many nociceptive and neuropathic pain conditions. Use of opioids for pain will be reviewed in a future issue.
Med Lett Drugs Ther. 2018 Feb 12;60(1540):24-32 | Show Full IntroductionHide Full Introduction

Comparison Table: Some Nonopioid Analgesics for Pain (online only)

   
The Medical Letter on Drugs and Therapeutics • February 12, 2018;  (Issue 1540)
...
View the Comparison Table: Some Nonopioid Analgesics for Pain
Med Lett Drugs Ther. 2018 Feb 12;60(1540):e32-5 | Show Full IntroductionHide Full Introduction

Low-Dose Meloxicam (Vivlodex) for Osteoarthritis Pain

   
The Medical Letter on Drugs and Therapeutics • March 14, 2016;  (Issue 1490)
The FDA has approved Vivlodex (Iroko), a low-dose formulation of the nonsteroidal anti-inflammatory drug meloxicam (Mobic, and generics), for management of osteoarthritis pain. According to the manufacturer,...
The FDA has approved Vivlodex (Iroko), a low-dose formulation of the nonsteroidal anti-inflammatory drug meloxicam (Mobic, and generics), for management of osteoarthritis pain. According to the manufacturer, the new formulation aligns with stronger FDA warnings about the cardiovascular risks of NSAIDs and the recommendation to use the lowest possible doses of these drugs.
Med Lett Drugs Ther. 2016 Mar 14;58(1490):35-6 | Show Full IntroductionHide Full Introduction

Drugs for Osteoarthritis

   
The Medical Letter on Drugs and Therapeutics • September 1, 2014;  (Issue 1450)
Many different drugs are used for treatment of osteoarthritis pain, but none of them prevent progression of the disease. Many nonpharmacologic approaches are available as well, including weight...
Many different drugs are used for treatment of osteoarthritis pain, but none of them prevent progression of the disease. Many nonpharmacologic approaches are available as well, including weight management, exercise, physical therapy, assistive devices, and total joint arthroplasty. New guidelines for the management of osteoarthritis have recently been published.
Med Lett Drugs Ther. 2014 Sep 1;56(1450):80-4 | Show Full IntroductionHide Full Introduction

In Brief: Low-Dose Indomethacin (Tivorbex) for Pain

   
The Medical Letter on Drugs and Therapeutics • July 21, 2014;  (Issue 1447)
The same pharmaceutical company (Iroko) that recently marketed low-dose diclofenac (Zorvolex) for treatment of mild to moderate acute pain1 has now received approval from the FDA to market a low-dose oral...
The same pharmaceutical company (Iroko) that recently marketed low-dose diclofenac (Zorvolex) for treatment of mild to moderate acute pain1 has now received approval from the FDA to market a low-dose oral formulation of indomethacin (Tivorbex) for the same indication. Tivorbex is available in 20- and 40-mg capsules; conventional immediate-release indomethacin capsules contain 25 mg and 50 mg of the drug.

The rationale for this new product is the same as the one offered for Zorvolex: the drug is formulated as submicron particles that increase surface area, leading to faster dissolution and absorption. According to the package insert, the time to reach peak serum concentrations (Tmax) was 1.67 hours with a 40-mg capsule of Tivorbex, compared to 2.02 hours with a standard 50-mg capsule of indomethacin.

The problem with Tivorbex is the same as the problem with Zorvolex: there are no studies comparing its efficacy to that of standard doses of indomethacin or to any other NSAID. In addition, indomethacin is generally considered one of the most potent NSAIDs and one of those most likely to cause GI bleeding, increase cardiovascular risk, and damage the kidneys. There is no good reason to use indomethacin in any dosage for treatment of mild to moderate pain.

  1. Low-dose diclofenac (Zorvolex) for pain. Med Lett Drugs Ther 2014; 56:19.


Download complete U.S. English article

Med Lett Drugs Ther. 2014 Jul 21;56(1447):64 | Show Full IntroductionHide Full Introduction

Low-Dose Diclofenac (Zorvolex) for Pain

   
The Medical Letter on Drugs and Therapeutics • March 3, 2014;  (Issue 1437)
The FDA has approved Zorvolex (Iroko), a low-dose oral formulation of the relatively COX-2 selective NSAID diclofenac, for treatment of mild-to-moderate acute pain in...
The FDA has approved Zorvolex (Iroko), a low-dose oral formulation of the relatively COX-2 selective NSAID diclofenac, for treatment of mild-to-moderate acute pain in adults.
Med Lett Drugs Ther. 2014 Mar 3;56(1437):19-20 | Show Full IntroductionHide Full Introduction